Visit
Genomic testing and clinical decision making in CLL
Advances in the understanding of the CLL genome has led to the use of genomic and molecular biomarkers such as TP53 genetic alterations and immunoglobulin heavy variable (IgHV) gene mutation status. Hear more below from leading experts in CLL on the importance of genomic testing, and the impact of these results on diagnosis, prognosis and guiding treatment decisions.
The content in this feature is updated regularly so please check back for further updates…
How is high-risk disease defined in CLL?
In this new video from the recent ERIC 2022 Meeting, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, reviews the significance of TP53 aberrations in defining high-risk disease in CLL.
6 Oct 2022
How is high-risk disease defined in CLL?
Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, explains that patients with TP53 aberration and unmutated IgHV are considered high-risk when chemo-immunotherapy is the only treatment option; however, in the age of novel agents, the definition of high-risk CLL is changing.
13 Apr 2022
Why is it important to perform testing in CLL?
In this new video from the recent ERIC 2022 Meeting, Antonio Cuneo, MD, St. Anna University Hospital, Ferrera, Italy, highlights the importance of genomic testing prior to treatment initiation in CLL, and how testing informs treatment decisions.
7 Oct 2022
NEW: Why is it important to perform testing in CLL?
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, highlights the importance of genomic tests such as fluorescence in situ hybridization (FISH) analysis, TP53 mutation screening and testing of IgHV mutational status to inform treatment decisions in patients with CLL.
13 Apr 2022
NEW PODCAST!
Prefer to listen? In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.
What is the importance of re-testing in CLL?
In this new video from the recent ERIC 2022 Meeting, Barbara Eichhorst, MD, University Hospital Cologne, Germany, discusses the importance of re-testing patients with CLL after relapse.
7 Oct 2022
What is the importance of re-testing in CLL?
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, discusses some of the key tests performed pre-treatment in patients with CLL, and that after relapse or disease progression, both FISH and TP53 analysis must be performed again to improve subsequent lines of treatment.
13 Apr 2022
TP53 testing in CLL – why is it important?
In this new video from the recent ERIC 2022 Meeting Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on the important role of TP53 in CLL.
7 Oct 2022
What is the importance of re-testing in CLL?
Lukas Frenzel, MD, University of Cologne, Cologne, Germany, evaluates the influence of testing for TP53 mutation of treatment decisions in CLL, the role of TP53 as a master regulator of apoptosis and the role that this gene plays in influencing patient responses to therapies.
13 Apr 2022
TP53 testing and IgHV status
In this new video from the recent ASH 2022 Meeting, Adam Kittai, MD, Ohio State University, Columbus, OH, explains how the prognostic value of IgHV status changes according to the therapy used in CLL.
10 Dec 2022
T
In this new video from the recent ASH 2022 Meeting,Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the importance of continuing genomic testing in CLL with the advent of targeted therapies.
12 Dec 2022
Treatment decisions: Impact of genomic testing
In this new video from the recent ERIC 2022 Meeting, Michel van Gelder, MD, PhD, Maastricht University, Maastricht, Netherlands, shares some insights into how patients with chronic lymphocytic leukemia (CLL) are involved in treatment decision-making following a genomic test.
7 Oct 2022
Treatment decisions: Impact of genomic testing
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, gives her thoughts on the need to monitor patients with high-risk cytogenetics closely and to incorporate genomic testing when considering time-limited or continuous treatment plans for patients.
13 Apr 2022
In this new video from the recent ASH 2022 Meeting, Adam Kittai, MD, Ohio State University, Columbus, OH, comments on the prognostic value of different adverse prognostic features in patients with CLL treated with continuous therapy with a BTK inhibitor versus time-limited therapy with venetoclax and obinutuzumab.
10 Dec 2022
In this new video from the recent ASH 2022 Meeting, Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses the results of a study evaluating the uptake of genomic testing for CLL in small centers, describing the different tests available, when they should be performed, and how they may impact treatment decisions
8 Dec 2022
Richard Rosenquist
Received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, and Roche
Lukas Frenzel
Abbvie Advisory board
Barbara Eichhorst
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
